港股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

生物醫藥B類股

613.394

0.000

漲家數：8

跌家數：1

平家數：25

市盈率：- -

高：613.394

開：613.394

低：613.394

收：613.394

成交量：- -

成交額：- -

市值：3,945.22億

流通市值：3,529.70億

資料載入中...

總覽新聞資訊

康寧傑瑞製藥-B(09966)：JSKN033一線治療晚期宮頸癌的II期臨床研究完成首例患者給藥

智通财经网

港版「FDA」年底前要成立了創新藥出海新增跳板

中信建投：醫藥零售行業業績和估值拐點明顯關注後續多元催化

轉型向「智」拓市向「雲」衡水冀州以數智賦能工業發展

中国新闻网

152億美元！恒瑞為何能讓全球製藥巨頭瘋狂？

21世纪经济报道

歐康維視生物-B(01477)授出購股權及獎勵

加科思-B(01167)5月12日斥資46.6萬港元回購7.89萬股

貝康醫療-B(02170)擬實施H股全流通計劃

歸創通橋(02190.HK)5月12日耗資113.6萬港元回購5.1萬股

創新藥再爆百億BD大單！華寶基金藥ETF逆市連陽！多頭提前埋伏，連續4日爆買520880！

GIC Private Limited增持歌禮制藥-B(01672)12.2萬股每股作價16.612港元

斥資7億，「果蔬第一股」玩醫藥，新控股股東能否力挽狂瀾？

再鼎醫藥(09688)：授出購股權及受限制股份單位

國泰海通：1Q26行業趨勢延續向好創新藥仍是醫藥板塊景氣主線

微創心通－Ｂ(02160)股價下跌5.328%，現價港幣$2.31

阿斯达克财经

利好突襲！3800億巨頭直線拉升，百億美元大單引爆創新藥概念

21世纪经济报道

黑永疆離開石藥創業，醫藥老兵「第三階段」想幹什麼？

21世纪经济报道

創新藥概念局部異動

恒瑞醫藥與BMS達成全球重磅合作，攜手開發13款早期創新藥

老虎资讯综合

《大行》摩通：醫保目錄調整加速創新藥商業化首選信達生物(01801.HK)藥明康德(02359.HK)藥明合聯(02268.HK)科倫博泰(06990.HK)

阿斯达克财经

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/BK1574/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1574","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","market":"HK","secType":"PLATE","nameCN":"生物醫藥B類股","latestPrice":613.3937,"timestamp":1778635445478,"preClose":613.3937,"halted":0,"volume":0,"delay":0,"changeRate":0,"floatShares":0,"shares":0,"eps":0,"marketStatus":"開市前","change":0,"latestTime":"05-13 09:24:05","open":613.3937,"high":613.3937,"low":613.3937,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1778635800000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1778635800000,1778644800000],[1778648400000,1778659200000]],"pbRate":4.803894,"peRate":-90.711909,"turnoverRate":0.002663,"increases":8,"decrements":1,"flats":24,"marketCap":394522475488,"floatMarketCap":352970313648},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","high":613.3937,"amplitude":0,"preClose":613.3937,"low":613.3937,"pbRate":"4.803894","latestPrice":613.3937,"volume":0,"delay":0,"open":613.3937,"prevYearClose":556.26263,"prevWeekClose":624.992,"prevMonthClose":639.5,"prevQuarterClose":610.821,"fiveDayClose":623.642,"twentyDayClose":672.448,"sixtyDayClose":547.905,"secType":"PLATE","market":"HK","turnoverRate":0.002663,"peRate":-90.711909,"marketCap":394522475488,"floatMarketCap":352970313648,"timestamp":1778635445505,"nameCN":"生物醫藥B類股"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1574\",,,,undefined,":{"bkCode":"BK1574","up":8,"down":1,"flat":25},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1574\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2635221155","title":"康寧傑瑞製藥-B(09966)：JSKN033一線治療晚期宮頸癌的II期臨床研究完成首例患者給藥","url":"https://stock-news.laohu8.com/highlight/detail?id=2635221155","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635221155?lang=zh_tw&edition=fundamental","pubTime":"2026-05-13 08:09","pubTimestamp":1778630957,"startTime":"0","endTime":"0","summary":"在早期临床研究中，JSKN033单药在经治晚期宫颈癌患者中已展现出优异疗效和可控安全性，为其一线联合治疗奠定了坚实基础。JSKN033-202是一项开放、多中心、II期临床研究，旨在评估JSKN033联合铂类化疗联合或不联合贝伐珠单抗一线治疗晚期宫颈癌患者的安全性、有效性及药代动力学╱药效学特征。所有患者将接受JSKN033联合顺铂或卡铂联合或不联合贝伐珠单抗的治疗。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1440966.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK1574","BK1161","09966"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635221153","title":"港版「FDA」年底前要成立了 創新藥出海新增跳板","url":"https://stock-news.laohu8.com/highlight/detail?id=2635221153","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635221153?lang=zh_tw&edition=fundamental","pubTime":"2026-05-13 08:06","pubTimestamp":1778630782,"startTime":"0","endTime":"0","summary":"【港版“FDA”年底前要成立了 创新药出海新增跳板】在亚洲医疗健康高峰论坛上，中国香港特别行政区行政长官李家超表示，今年3月，中国香港开始在实施药物注册“第一层审评”，这是迈向2030年全面实现独立药物审评审批的里程碑，香港药物及医疗器械监督管理中心也将在今年年底前成立。目前中国香港没有本土的药物审批机构，大量的创新药仍需要在其他地区进行审批之后才能引入市场。近年来，香港在优化创新药物的评估及审批机制。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"eastmoney_highlight","url":"http://hk.eastmoney.com/news/11792,202605123734860751.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://hk.eastmoney.com/news/11792,202605123734860751.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"eastmoney_highlight","symbols":["BK4585","159992","06978","BK1161","BK4588","LABU","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635822183","title":"中信建投：醫藥零售行業業績和估值拐點明顯 關注後續多元催化","url":"https://stock-news.laohu8.com/highlight/detail?id=2635822183","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635822183?lang=zh_tw&edition=fundamental","pubTime":"2026-05-13 07:43","pubTimestamp":1778629394,"startTime":"0","endTime":"0","summary":"血制品行业关注“十五五”浆站建设规划及行业并购整合进展，期待后续需求端复苏及新品研发。医药零售行业后续业绩拐点和估值拐点明显，关注后续多元催化。长期建议关注基药目录等政策催化及行业转型升级进展。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1440956.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09939","BK1515","BK1574","BK0276","159938","BK1161","601066"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634774210","title":"轉型向「智」拓市向「雲」 衡水冀州以數智賦能工業發展","url":"https://stock-news.laohu8.com/highlight/detail?id=2634774210","media":"中国新闻网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634774210?lang=zh_tw&edition=fundamental","pubTime":"2026-05-12 22:18","pubTimestamp":1778595480,"startTime":"0","endTime":"0","summary":"中新网衡水5月12日电 题：转型向“智”拓市向“云” 衡水冀州以数智赋能工业发展作者 李玉素 谌诗雨 王鹏“大家现在看到的是我们专为失能、半失能老人推出的多功能护理床，背腿联动、一键操作，大大减轻家人照护压力。”李玉素 摄这是河北省衡水市冀州区推进 “一品一播” 行动、以数智赋能工业发展的日常场景。如今，该企业依托冀州区“一品一播”基地大力开拓市场，实现内外销双向发力、协同增长。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/roll/2026-05-12/doc-inhxsawi5099302.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2026-05-12/doc-inhxsawi5099302.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1583","BK1100","09996","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634107952","title":"152億美元！恒瑞為何能讓全球製藥巨頭瘋狂？","url":"https://stock-news.laohu8.com/highlight/detail?id=2634107952","media":"21世纪经济报道","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634107952?lang=zh_tw&edition=fundamental","pubTime":"2026-05-12 22:11","pubTimestamp":1778595060,"startTime":"0","endTime":"0","summary":"5月12日午盘，恒瑞医药突然放出一枚深水炸弹：和全球制药巨头百时美施贵宝（BMS）达成了重磅合作！这笔买卖到底有多大？潜在总交易额高达152亿美元！BMS先支付9.5亿美元首付和近期付款，后面只要药物研发能顺利推下去，恒瑞还能拿到上百亿的里程碑付款，甚至未来的销售分成！这次合作涉及13款早期创新药，主攻肿瘤、血液和免疫疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202605123734849437.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605123734849437.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["01477","BK1191","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634212162","title":"歐康維視生物-B(01477)授出購股權及獎勵","url":"https://stock-news.laohu8.com/highlight/detail?id=2634212162","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634212162?lang=zh_tw&edition=fundamental","pubTime":"2026-05-12 21:26","pubTimestamp":1778592417,"startTime":"0","endTime":"0","summary":"智通财经APP讯，欧康维视生物-B 发布公告，董事会认为有必要实施激励措施以支持本集团的战略增长目标，并维持人才招聘及留任方面的竞争优势。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1440893.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01477","BK1574","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634214323","title":"加科思-B(01167)5月12日斥資46.6萬港元回購7.89萬股","url":"https://stock-news.laohu8.com/highlight/detail?id=2634214323","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634214323?lang=zh_tw&edition=fundamental","pubTime":"2026-05-12 20:57","pubTimestamp":1778590679,"startTime":"0","endTime":"0","summary":"智通财经APP讯，加科思-B(01167)发布公告，于2026年5月12日斥资46.6万港元回购7.89万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1440877.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","01167","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634219560","title":"貝康醫療-B(02170)擬實施H股全流通計劃","url":"https://stock-news.laohu8.com/highlight/detail?id=2634219560","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634219560?lang=zh_tw&edition=fundamental","pubTime":"2026-05-12 20:09","pubTimestamp":1778587773,"startTime":"0","endTime":"0","summary":"智通财经APP讯，贝康医疗-B(02170)公布，董事会已审议及批准建议实施H股全流通，以转换合共约1.91亿股公司未上市股份为公司H股。待取得所有相关批准及╱或备案(包括中国证监会的备案通知及联交所的批准)并符合所有适用法律、法规及规则后，该等未上市股份将转换为H股，且公司将申请批准该等H股于联交所主板上市及买卖。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1440856.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1222","BK1597","02170","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634216688","title":"歸創通橋(02190.HK)5月12日耗資113.6萬港元回購5.1萬股","url":"https://stock-news.laohu8.com/highlight/detail?id=2634216688","media":"中金财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634216688?lang=zh_tw&edition=fundamental","pubTime":"2026-05-12 19:47","pubTimestamp":1778586424,"startTime":"0","endTime":"0","summary":"格隆汇5月12日丨归创通桥(02190.HK)公告，5月12日耗资113.6万港元回购5.1万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260512/32218487.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["02190","BK1583","BK1587","BK1574","BK1100"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634215477","title":"創新藥再爆百億BD大單！華寶基金藥ETF逆市連陽！多頭提前埋伏，連續4日爆買520880！","url":"https://stock-news.laohu8.com/highlight/detail?id=2634215477","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634215477?lang=zh_tw&edition=fundamental","pubTime":"2026-05-12 19:38","pubTimestamp":1778585880,"startTime":"0","endTime":"0","summary":"5月12日，AH创新药整体延续调整。午间恒瑞医药官宣重磅BD，其A股暴拉涨停，H股一度冲涨16%，带动板块直线拉升翻红。　　A股制药板块午后自深水区拉起，场内唯一药ETF华宝*直线冲高1.73%根据PCF清单，恒瑞医药为药ETF华宝第一大权重股，最新权重占比14.13%。　　截至收盘，药ETF华宝逆市收涨，成功连阳站上10日线。2026年一季度，中国创新药对外BD的平均首付款为1.8亿美元，相比2025年增长59%，相比5年前更是大涨187%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-05-12/doc-inhxrwqe1459758.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1161","159992","BK1574","520880","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634021349","title":"GIC Private Limited增持歌禮制藥-B(01672)12.2萬股 每股作價16.612港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2634021349","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634021349?lang=zh_tw&edition=fundamental","pubTime":"2026-05-12 19:07","pubTimestamp":1778584055,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新数据显示，5月7日，GIC Private Limited增持歌礼制药-B(01672)12.2万股，每股作价16.612港元，总金额约为202.67万港元。增持后最新持股数目为7480.8万股，最新持股比例为7.00%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1440802.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1515","01672","BK1191","BK1161","GIC","BK4104","BK1574","EWH","01477"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634724291","title":"斥資7億，「果蔬第一股」玩醫藥，新控股股東能否力挽狂瀾？","url":"https://stock-news.laohu8.com/highlight/detail?id=2634724291","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634724291?lang=zh_tw&edition=fundamental","pubTime":"2026-05-12 17:08","pubTimestamp":1778576880,"startTime":"0","endTime":"0","summary":"炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！　　它就是有着“果蔬第一股”之称的宏辉果蔬。　　近期，宏辉果蔬发布公告，拟斥资7亿元收购江西施美药业41.128%股权，完成收购后，施美药业将成为宏辉果蔬控股子公司，并表进入上市公司。2016年公司在上交所上市，成为资本市场备受瞩目的“果蔬第一股”。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/wm/2026-05-12/doc-inhxrshk9915717.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1515","BK1161","159938","BK1574","09939"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634299314","title":"再鼎醫藥(09688)：授出購股權及受限制股份單位","url":"https://stock-news.laohu8.com/highlight/detail?id=2634299314","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634299314?lang=zh_tw&edition=fundamental","pubTime":"2026-05-12 16:34","pubTimestamp":1778574847,"startTime":"0","endTime":"0","summary":"智通财经APP讯，再鼎医药(09688)发布公告，公司于授出日期根据2024年股权激励计划授出13.68万份购股权(以美国存托股份计)、7.53万份受限制股份单位(以美国存托股份计)。所授出购股权涉及的相关股份数目：1,368,190;所授出受限制股份单位涉及的相关股份数目：752,880。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1440675.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4139","BK4531","BK4588","LU2488822045.USD","09688","BK1161","BK4548","ZLAB","BK4526","BK4585","BK1588","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634295796","title":"國泰海通：1Q26行業趨勢延續向好 創新藥仍是醫藥板塊景氣主線","url":"https://stock-news.laohu8.com/highlight/detail?id=2634295796","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634295796?lang=zh_tw&edition=fundamental","pubTime":"2026-05-12 15:57","pubTimestamp":1778572645,"startTime":"0","endTime":"0","summary":"创新药销售与BD收入形成双轮驱动，行业增长结构持续优化2025年药企创新药相关收入，即创新药销售收入与BD收入合计约1940亿元，同比+35%，占药品板块总收入比例已提升至42%。商业化Biotech受益于收入规模快速扩大，销售费用率明显摊薄，盈利拐点进一步明确。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1440652.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1564","BK1161","BK0201","02611","BK0012","159938","BK0028","BK0276","BK1515","159992","09939","BK0184","BK0183","BK1147","06978","BK1574","601211","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634341260","title":"微創心通－Ｂ(02160)股價下跌5.328%，現價港幣$2.31","url":"https://stock-news.laohu8.com/highlight/detail?id=2634341260","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634341260?lang=zh_tw&edition=fundamental","pubTime":"2026-05-12 14:35","pubTimestamp":1778567700,"startTime":"0","endTime":"0","summary":"[下跌股]微创心通－Ｂ(02160) 股价在下午02:35比前收市价下跌5.328%，现股价为港币$2.31。至目前为止，今日最高价为$2.45，而最低价为$2.31。总成交量为75.72万股，总成交金额为港币$177.724万。","market":"hk","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180126135515084_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180126135515084_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2605122231/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2605122231/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1583","02160","BK1574","BK1100"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634625572","title":"利好突襲！3800億巨頭直線拉升，百億美元大單引爆創新藥概念","url":"https://stock-news.laohu8.com/highlight/detail?id=2634625572","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634625572?lang=zh_tw&edition=fundamental","pubTime":"2026-05-12 14:14","pubTimestamp":1778566440,"startTime":"0","endTime":"0","summary":"5月12日，创新药概念局部异动。其中，恒瑞医药（600276.SH）午后直线拉涨，随后回落，截至13:35，报56.61元/股，涨5.77%，总市值3757亿元；重药控股（000950.SZ）、津药药业（600488.SH）涨停，华兰股份（301093.SZ）、成都先导（688222.SH）等多只概念股涨超5%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202605123734373335.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605123734373335.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1574","06978","BK1161","159992"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634584262","title":"黑永疆離開石藥創業，醫藥老兵「第三階段」想幹什麼？","url":"https://stock-news.laohu8.com/highlight/detail?id=2634584262","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634584262?lang=zh_tw&edition=fundamental","pubTime":"2026-05-12 14:10","pubTimestamp":1778566200,"startTime":"0","endTime":"0","summary":"5月6日，工信部刚刚公布了石药集团入选2025年数字化转型典型案例的消息。然而就在几天之后，这艘老牌航母刚刚完成“航母+AI”的华丽转身，正朝着创新药全球化全力调头之际，又一则重磅消息搅动了整个生物医药圈。　　市场消息显示，石药集团执行总裁、全球首席医学官黑永疆博士，已从石药集团正式离职，创立上海慧思博生物医药科技有限公司。　　企业信息显示，慧思博生物成立于2026年4月13日，注册资本500万元，位于上海青浦区。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/2026-05-12/doc-inhxrmyk1526070.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/2026-05-12/doc-inhxrmyk1526070.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU0314109678.HKD","LU2039709279.SGD","LU0315179316.USD","LU1226288170.HKD","LU1328277881.USD","LU0140636845.USD","BK1521","LU1813983027.USD","LU1960683339.HKD","BK1574","LU0880133367.SGD","IE00B031HY20.USD","IE00B5MMRT66.SGD","LU1152091168.USD","LU1226287875.USD","LU1807302812.USD","LU0067412154.USD","LU1951186391.HKD","LU0072913022.USD","IE0008368742.USD","LU0501845795.SGD","LU1008478684.HKD","LU1226287529.USD","IE00BZ08YT58.USD","LU1993786604.SGD","SG9999004220.SGD","BK1161","LU1226287792.SGD","LU1226288253.USD","HK0000165453.HKD","LU1152091754.HKD","BK1515","BK1191","IE0008369823.USD","IE00B543WZ88.USD","159938","161022","LU0326950275.SGD","IE00BZ08YS42.EUR","IE00BZ08YR35.GBP","01093","09939"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634269896","title":"創新藥概念局部異動","url":"https://stock-news.laohu8.com/highlight/detail?id=2634269896","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634269896?lang=zh_tw&edition=fundamental","pubTime":"2026-05-12 13:07","pubTimestamp":1778562453,"startTime":"0","endTime":"0","summary":"创新药概念局部异动","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202605123734314845.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605123734314845.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1574","BK1161","06978","159992"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198821818","title":"恒瑞醫藥與BMS達成全球重磅合作，攜手開發13款早期創新藥","url":"https://stock-news.laohu8.com/highlight/detail?id=1198821818","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1198821818?lang=zh_tw&edition=fundamental","pubTime":"2026-05-12 13:03","pubTimestamp":1778562223,"startTime":"0","endTime":"0","summary":"5月12日，$恒瑞医药(01276)$午后直线拉升，一度涨超16%！该公司与BMS达成全球重磅合作，携手开发13款早期创新药。","market":"hk","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"b1f4c1fa965d76d4e78087079f689b4e","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":"恒瑞医药与BMS达成全球重磅合作，携手开发13款早期创新药","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2580892789.USD","BK0012","BMY","LU2289578879.USD","LU1655091616.SGD","LU1997245094.SGD","BK1161","LU1064130708.USD","LU0359201885.HKD","159992","BK1191","LU2097828631.EUR","LU1146622755.USD","LU0405327494.USD","LU1064131003.USD","LU2495084118.USD","LU2580892862.HKD","LU2148510915.USD","LU1023057109.AUD","BK0183","LU0405327148.USD","BK1574","LU2097828805.USD","BK0188","01276","LU1580142542.USD","LU1781817850.SGD","LU2097828714.EUR","LU2097828474.EUR","LU1997244956.HKD","LU0359202008.SGD","LU2097828557.USD","BK0028","BK0060","BK0196","LU1255011170.USD","LU1328615791.USD","LU0359201612.USD","LU2328871848.SGD","LU1820825898.SGD","BK0239","LU1997245177.USD","LU1969619763.USD","LU2543165471.USD","LU2488822045.USD","600276"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2634636272","title":"《大行》摩通：醫保目錄調整加速創新藥商業化  首選信達生物(01801.HK)藥明康德(02359.HK)藥明合聯(02268.HK)科倫博泰(06990.HK)","url":"https://stock-news.laohu8.com/highlight/detail?id=2634636272","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634636272?lang=zh_tw&edition=fundamental","pubTime":"2026-05-12 11:49","pubTimestamp":1778557740,"startTime":"0","endTime":"0","summary":"报告指出，商业保险至国家医保目录的桥接路径正式确立，验证了许多创新药公司一直追求的双重清单策略。目前被商业保险覆盖但未纳入国家医保目录的药物，因零售价过往超出医保谈判的接受范围，新规对此类药物尤其有意义。摩根大通重申对信达生物、科伦博泰、药明康德及药明合联的正面看法，并将其列为行业首选股。","market":"other","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20190401142440846_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20190401142440846_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1524013/latest-news/AAFN","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1524013/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1583","LU1979443071.USD","LU0502904849.HKD","01801","LU0348766576.USD","LU2097828557.USD","LU2097828714.EUR","LU1969619763.USD","LU1046422090.SGD","LU2495084118.USD","LU1719994722.HKD","LU0052750758.USD","LU1303224171.USD","LU1997244956.HKD","LU0708995583.HKD","LU2097828474.EUR","LU2125910500.SGD","LU0196878994.USD","LU0348767384.USD","LU1251922891.USD","SG9999014674.SGD","BK1589","LU1997245094.SGD","LU2488822045.USD","LU2328871848.SGD","02268","BK1161","06978","LU1997245177.USD","LU1934453819.USD","LU2045819591.USD","BK1574","603259","LU2097828805.USD","BK1576","HK0000165453.HKD","LU0455707207.USD","06990","LU1770034418.SGD","LU1808992512.USD","BK0216","159992","LU2097828631.EUR","LU0320764599.SGD","LU0456842615.SGD","02359","LU2242644610.SGD","BK1141"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":1,"totalSize":200,"code":"91000000","status":"200"}]}}